title: Comparison of different methods to investigate postprandial lipaemia.
abstract: Postprandial hyperlipidaemia has been associated with coronary artery disease (CAD). We investigated which of the generally used methods to test postprandial lipaemia differentiated best between patients with premature CAD (50+/-4 years, n=20) and healthy controls. Furthermore, the effects of rosuvastatin 40 mg/day on postprandial parameters were assessed. Standardised oral fat-loading tests (OFLT) and ambulant self-measurements of daylong capillary triglycerides (TGc) were performed. Total responses of individual lipoproteins, plasma TG (TGp) and remnant-like particle cholesterol (RLP-C) were estimated as area under the curve (AUC). Most AUCs were highest in untreated patients and reached control levels after rosuvastatin. From all AUCs, RLP-C-AUC was best associated to TGp-AUC in untreated patients and controls (adjusted R2=0.84, beta=0.92, p.
authors.affiliation: Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands.
authors.forename: A J H H M
authors.initials: AJ
authors.lastname: van Oostrom
authors.forename: A
authors.initials: A
authors.lastname: Alipour
authors.forename: T P
authors.initials: TP
authors.lastname: Sijmonsma
authors.forename: C
authors.initials: C
authors.lastname: Verseyden
authors.forename: G M
authors.initials: GM
authors.lastname: Dallinga-Thie
authors.forename: H W M
authors.initials: HW
authors.lastname: Plokker
authors.forename: M
authors.initials: M
authors.lastname: Castro Cabezas
mesh_terms: D019540:Area Under Curve; D003324:Coronary Artery Disease / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology; D005260:Female; D005464:Fluorobenzenes / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006949:Hyperlipidemias / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D019518:Postprandial Period; D011743:Pyrimidines / Q000627:therapeutic use; D012044:Regression Analysis; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000627:therapeutic use; D014280:Triglycerides / Q000097:blood
chemical_list: D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids; D011743:Pyrimidines; D013449:Sulfonamides; D014280:Triglycerides; D000068718:Rosuvastatin Calcium